Zobrazeno 1 - 10
of 166
pro vyhledávání: '"Michael I Nishimura"'
Autor:
Long Chen, David F Stroncek, Gang Zeng, Steven Highfill, Robert Reger, Stefan Barisic, Elena Cherkasova, Elizabeth M Brahmbhatt, Timothy T Spear, Ujjawal Savani, Stephanie Pierre, Gina M Scurti, Muna Igboko, Rosa Nadal, Gordon Parry, Annika V Dalheim, Michael I Nishimura, Richard W Childs
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 9 (2024)
Background We discovered a novel human endogenous retrovirus (CT-RCC HERV-E) that was selectively expressed in most clear cell renal cell carcinomas (ccRCC) and served as a source of antigens for T cell-mediated killing. Here, we described the clonin
Externí odkaz:
https://doaj.org/article/bdd7b926eb5a41dab026790fbcaa4b31
Autor:
Yi Zhang, Yeuying Liu, Kelly M Moxley, Lucy Golden-Mason, Michael G Hughes, Tongxin Liu, Mirjam H M Heemskerk, Hugo R Rosen, Michael I Nishimura
Publikováno v:
PLoS Pathogens, Vol 6, Iss 7, p e1001018 (2010)
Hepatitis C Virus (HCV) is a major public health concern, with no effective vaccines currently available and 3% of the world's population being infected. Despite the existence of both B- and T-cell immunity in HCV-infected patients, chronic viral inf
Externí odkaz:
https://doaj.org/article/52aa547cdf234f33a0cd08927f35c3f2
Autor:
Todd M Brusko, Richard C Koya, Shirley Zhu, Michael R Lee, Amy L Putnam, Stephanie A McClymont, Michael I Nishimura, Shuhong Han, Lung-Ji Chang, Mark A Atkinson, Antoni Ribas, Jeffrey A Bluestone
Publikováno v:
PLoS ONE, Vol 5, Iss 7, p e11726 (2010)
Therapies directed at augmenting regulatory T cell (Treg) activities in vivo as a systemic treatment for autoimmune disorders and transplantation may be associated with significant off-target effects, including a generalized immunosuppression that ma
Externí odkaz:
https://doaj.org/article/869e52c785f74606a021f6ec8c540992
Autor:
Nishant K. Singh, Jesus A. Alonso, Jason R. Devlin, Grant L. J. Keller, George I. Gray, Adarsh K. Chiranjivi, Sara G. Foote, Lauren M. Landau, Alyssa G. Arbuiso, Laura I. Weiss, Aaron M. Rosenberg, Lance M. Hellman, Michael I. Nishimura, Brian M. Baker
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-14 (2022)
MHC restriction depicts CD4+ T cell activation by MHC-II and CD8A+ by MHC-I, but rare T cells with mismatched MHC restriction have been reported. Here the authors use crystallography to describe features of such a mismatched TCR-MHC interaction and i
Externí odkaz:
https://doaj.org/article/0743243588da4db7b9427d68ad78e7b9
Autor:
Xueliang Gao, Yongxia Wu, Joel M. Chick, Andrea Abbott, Baishan Jiang, David J. Wang, Susana Comte-Walters, Roger H. Johnson, Nathaniel Oberholtzer, Michael I. Nishimura, Steven P. Gygi, Anand Mehta, Denis C. Guttridge, Lauren Ball, Shikhar Mehrotra, Piotr Sicinski, Xue-Zhong Yu, Haizhen Wang
Publikováno v:
Cell Reports, Vol 42, Iss 4, Pp 112314- (2023)
Summary: Elucidating the mechanisms of resistance to immunotherapy and developing strategies to improve its efficacy are challenging goals. Bioinformatics analysis demonstrates that high CDK6 expression in melanoma is associated with poor progression
Externí odkaz:
https://doaj.org/article/d8061c0240544238ba7cf4290e1b4efe
Autor:
Tamson V. Moore, Gina M. Scurti, Matthew DeJong, Siao-Yi Wang, Annika V. Dalheim, Courtney R. Wagner, Kelli A. Hutchens, Jodi J. Speiser, Constantine V. Godellas, Chris Fountain, Jessica Fleser, Tarsem Moudgil, Mallory Thomas, David Murray, Brendan D. Curti, Joseph I. Clark, Bernard A. Fox, Michael I. Nishimura
Publikováno v:
Molecular Therapy: Oncolytics, Vol 20, Iss , Pp 352-363 (2021)
T cells that are gene-modified with tumor-specific T cell receptors are a promising treatment for metastatic melanoma patients. In a clinical trial, we treated seven metastatic melanoma patients with autologous T cells transduced to express a tyrosin
Externí odkaz:
https://doaj.org/article/89a5e7e4a04a46e287fbf116f56ea560
Autor:
Suzanne Quinn, Natasha Lenart, Victoria Dronzek, Gina M. Scurti, Nasheed M. Hossain, Michael I. Nishimura
Publikováno v:
Vaccines, Vol 10, Iss 3, p 457 (2022)
Immunotherapy is a beneficial treatment approach for multiple cancers, however, current therapies are effective only in a small subset of patients. Adoptive cell transfer (ACT) is a facet of immunotherapy where T cells targeting the tumor cells are t
Externí odkaz:
https://doaj.org/article/a143d7add8e7460fbf251ae60183ed45
Autor:
Estefania Gauto-Mariotti, Amanda J. Nguyen, Chloe Waters, Gina M. Scurti, Sandra Haddad, Milind M. Velankar, Annika V. Dalheim, Victoria Dronzek, Rhett P. Ketterling, Michael I. Nishimura, Joanna C. Dalland, Nasheed M. Hossain
Publikováno v:
Journal of Hematopathology. 15:229-237
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1767ee53e821871154f3811f6635f645
https://doi.org/10.1007/s12308-022-00519-2
https://doi.org/10.1007/s12308-022-00519-2
Autor:
Shikhar Mehrotra, Carolyn D. Britten, Steve Chin, Elizabeth Garrett-Mayer, Colleen A. Cloud, Mingli Li, Gina Scurti, Mohamed L. Salem, Michelle H. Nelson, Melanie B. Thomas, Chrystal M. Paulos, Andres M. Salazar, Michael I. Nishimura, Mark P. Rubinstein, Zihai Li, David J. Cole
Publikováno v:
Journal of Hematology & Oncology, Vol 10, Iss 1, Pp 1-13 (2017)
Abstract Background Dendritic cells (DCs) enhance the quality of anti-tumor immune response in patients with cancer. Thus, we posit that DC-based immunotherapy, in conjunction with toll-like receptor (TLR)-3 agonist poly-ICLC, is a promising approach
Externí odkaz:
https://doaj.org/article/24af04bf4a4248ecafa4d737c8c57263
Autor:
Cormac Cosgrove, Emilia R. Dellacecca, Michael I. Nishimura, I. Caroline Le Poole, Hans E. N. Bergmans
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1 (2019)
Tumor immunotherapy using gene-modified T cells has already met with considerable success in the treatment of metastatic melanoma and B cell lymphoma. With improving patient prognoses, new questions arise. In particular, the long-term consequences of
Externí odkaz:
https://doaj.org/article/145c95d215cc4b3fb69f8db492a7a925